Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...
As of December 31, 2024, the Company had consolidated cash, cash equivalents, restricted cash, and marketable securities of approximately ...
Reports Q3 revenue $9.02M, consensus $4.75M. “Roivant has broadened our clinical pipeline with the newly announced trial of brepocitinib in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback